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Abstract: Azithromycin is an azalide that acts by binding to the 50S ribosomal subunit of 
susceptible microorganisms and interfering with microbial protein synthesis. Azithromycin is 
also noted by anti-inflammatory and immunomodulatory activity. AzaSite® (Inspire Pharmaceu-
ticals, Inc, Durham, NC) is azithromycin ophthalmic solution, 1% formulated in polycarbophil 
(the aqueous mucoadhesive polymer contained in DuraSite®) that delivers high and prolonged 
azithromycin concentrations in a variety of ocular tissues, including the conjunctiva, cornea 
and particularly the eyelid. AzaSite was approved by the Food and Drug Administration (FDA) 
in the US in 2007, for the treatment of bacterial conjunctivitis caused by susceptible isolates. 
This article aims to evaluate the peer-reviewed published scientific literature and to define well-
established uses of AzaSite eye drops in the field of ocular infections.
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Introduction
Azithromycin is an azalide, a subclass of macrolide antibiotics (Figure 1). AzaSite® 
(Inspire Pharmaceuticals, Inc, Durham, NC) is azithromycin ophthalmic solution, 
1% formulated in polycarbophil (the aqueous mucoadhesive polymer contained in 
DuraSite®) that delivers the active drug to ocular surface tissues, over a period of 
time in a controlled fashion.1 Azithromycin is one of the few antibiotic classes that 
achieve therapeutic concentrations in the eye lids. The combination of inherent anti-
inflammatory properties along with the high and prolonged tissue concentrations1,2 
suggest that azithromycin ophthalmic solution, 1% has potential to serve as a treatment 
option for patients experiencing a wide range of conditions associated with the lid 
margin and ocular surface. AzaSite has been widely used by the ophthalmologists for 
various different indications in the field of ocular surface diseases.
Antimicrobial and anti-inflammatory  
action of azithromycin
Azithromycin exhibits a broad spectrum activity against Gram-positive, Gram-negative, 
and atypical bacteria, by binding to the 50S ribosomal subunit of susceptible microor-
ganisms and interfering with microbial protein synthesis. In 2007, the first ophthalmic 
formulation of azithromycin was approved by the Food and Drug Administration (FDA) 
in the US for the treatment of bacterial conjunctivitis caused by susceptible isolates 
(Table 1).3 Azithromycin has potency up to four times higher than erythromycin against 
Haemophilus influenza and Neisseria gonorrhea.4 Azithromycin is particularly   effective Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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against the intracellular organism Chlamydia   trachomatis, the 
main cause of preventable blindness in developing countries, 
which affects the conjunctiva and lids.5
A large body of preclinical and clinical observations 
has shown that azithromycin has anti-inflammatory and 
immunomodulatory properties independent of its antibacte-
rial effect by virtue of its ability to inhibit the synthesis of 
proinflammatory mediators and cytokines by monocytes 
and epithelial cells, suppress the NF-κB signal transduction 
pathway, inhibit matrix metalloproteinases 2 and 9, pro-
mote expression of the anti-inflammatory cytokine IL-10, 
and inhibit the migration of inflammatory cells.6–11 In vitro 
studies indicate that azithromycin is highly concentrated 
within polymorphonuclear leukocytes, which gravitate by 
chemotactic mechanisms to sites of infection. The high 
intracellular concentration of azithromycin in inflammatory 
fluids of abscesses supports the observation of concentration-
dependent killing of bacteria and prolonged persistent effects 
in tissues.1 In the setting of a murine model of surgically 
induced corneal inflammation, topical AzaSite twice daily 
led to significant suppression of corneal inflammation at 
the molecular and cellular levels (ie, significant decrease 
in messenger RNA expression levels of IL-1β, TNF-α and 
ICAM-1 in the cornea, and corneal leukocyte infiltration), 
although no anti-angiogenic effects were seen.12
The azithromycin ophthalmic 
solution, 1% (AzaSite®)
Given the hydrophobic nature of azithromycin, the aqueous 
ophthalmic preparations are not stable at room temperature. 
On the other hand, DuraSite is a polycarbophil (polymer of 
polyacrylic acid) bio-adhesive support matrix that allows 
longer persistence of the active compound on the eye sur-
face, by forming hydrogen bonds with glycosaminoglycans 
in mucus. It releases the neutral, anionic and cationic small 
molecules that it binds with over a period of time in a con-
trolled fashion.13 When a drop of AzaSite is applied to the 
ocular surface, the polymer returns to a gel state, which limits 
its loss through reflex tearing and naso-lacrimal drainage. 
Thus, the azithromycin formulation in DuraSite stays in 
contact with the ocular surface, delivering the drug over a 
period of hours,14 increasing the overall bioavailability of 
azithromycin.2 This property facilitates topical delivery of 
azithromycin and offers the benefit of a less-frequent dosing 
regimen. Additionally, in vitro studies have shown that the 
killing spectrum of 1% azithromycin in DuraSite appeared 
to be enhanced compared to the solution without DuraSite.15 
DuraSite was found to play a greater role in the inhibition of 
staphylococcal biofilm formation by AzaSite, compared to 
azithromycin which only had a moderate inhibitory effect.16 
In a clinical trial, 1% azithromycin in DuraSite eliminated 
82% of Staphylococcus aureus, including some species that 
were considered resistant to azithromycin.17
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Figure 1 The chemical structure of the azithromycin molecule.
Table 1 Antimicrobial activity of azithromycin
Azithromycin has been shown to be efficacious  
on the following ocular pathogens:
Hemophilus influenzae
Staphylococcus aureus
Streptococcus mitis group
Streptococcus pneumoniae
CDC coryneform group G (efficacy studied in fewer than 10 infections)
Azithromycin has shown in vitro minimum inhibitory 
concentrations of equal or less against most ($90%) of isolates 
of the following ocular pathogens:
Chlamydia pneumoniae
Chlamydia trachomatis
Legionella pneumophila
Moraxella catarrhalis
Mycoplasma hominis
Mycoplasma pneumoniae
Neisseria gonorrhoeae
Peptostreptococcus species
Streptococci (Groups C, F, G)
Streptococcus pyogenes
Streptococcus agalactiae
Ureaplasma urealyticum
viridans group streptococci.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Pharmacokinetics of azithromycin
Following oral administration, azithromycin is character-
ized by high-tissue distribution and prolonged elimination 
half-life, with relatively low plasma levels.18,19 It is taken up 
mainly by phagocytic cells and fibroblasts. During active 
phagocytosis, large concentrations of azithromycin are 
released directly to the site of infection.20,21 Plasma concentra-
tions of azithromycin decrease in a polyphasic pattern, with 
an average terminal half-life of elimination of 68 hours.22
Studies that examined the ocular pharmacokinetics 
  following oral administration of azithromycin in rabbits23,24 
and in human subjects undergoing cataract surgery,25 revealed 
high drug concentrations in the tissues (ie, cornea,   conjunctiva, 
iris, ciliary body) in contrast to relatively low concentrations 
in fluids (ie, vitreous humor and aqueous humor). This unique 
ocular distribution of azithromycin provides the rationale for 
the effectiveness of single   administration oral azithromycin 
for the treatment of trachoma.5
Ocular pharmacokinetics after ocular administration 
was studied on 120 pigmented rabbits that were equally 
assigned to two groups (ie, 1% azithromycin formulated 
with the polymer polycarbophil (AzaSite) vs azithromy-
cin   ophthalmic solution without polycarbophil.).2 Each 
group received a single 30 µL eye drop of drug, which was 
  deposited onto the center of the cornea. Peak concentrations 
of   azithromycin in the tear film, conjunctiva and cornea 
with the 1% azithromycin with polycarbophil formulation 
were between 5- and 12-fold higher than those observed 
  without polycarbophil; which persisted for the duration of 
the observation (ie, 7 days), indicating that the polycarbophil 
formulation increased the bioavailability of azithromycin. 
Additionally, the exposure of azithromycin measured as the 
area under curve (AUC) in the tear film following a single 
instillation was 3016 µg*h/g in the polycarbophil-containing 
formulation and 155 µg*h/g in the formulation without 
  polycarbophil, representing a 19.5-fold increase of exposure 
for the   formulation with polycarbophil. Consistent with the 
tendency of azithromycin to distribute preferentially in the 
tissues, the levels of azithromycin observed in the aqueous 
humor following ocular administration of both formulations 
were relatively low. The exposure of azithromycin in the 
eyelids 6 days after the last instillation in the multiple admin-
istration study was more than 2-fold higher than that observed 
in the conjunctiva. It was concluded that   azithromycin may 
potentially be used in the treatment of ocular surface disor-
ders that require chronic suppressive antibiotic treatment 
with or without anti-inflammatory effects. Following the 
FDA-approved dosing regimen for the treatment of bacterial 
conjunctivitis (ie, one drop twice a day for 2 days, followed 
by one drop per day for 5 days),3 clinically meaningful 
concentrations of azithromycin in the conjunctiva, cornea, 
and eyelids were observed as early as 1 hour after the first 
administration and the level of azithromycin remained high 
for up to 6 days after the end of treatment, providing thera-
peutic antibacterial levels of the drug.2
In the same study, an additional 156 pigmented rabbits 
received a 30 µL eye drop in the right eye following the 
FDA-approved dosing regimen for the treatment of bacterial 
conjunctivitis. Azithromycin was absorbed rapidly; and the 
peak concentrations continued to increase from dose-to-dose 
in the conjunctiva, cornea and eyelids throughout the 7-day 
treatment period, while trough concentrations stabilized 
within the first 2–3 days of dosing. The AUC(144–288 h) after 
the last dose was 4.2-fold greater in conjunctiva, 19.6-fold 
greater in cornea, and 13.3-fold greater in aqueous humor 
compared to AUC(0–144 h) after a single dose.2
Another study on the pharmacokinetic properties of a 
1.5% azithromycin ophthalmic formulation in a medium 
chain triglyceride oil formulation in rabbits also reported high 
levels of drug concentration in the cornea and conjunctiva 
in contrast to relatively low levels in the aqueous humor 
after single and multiple administrations. In that study, the 
maximal concentrations of azithromycin achieved in all tis-
sues were lower than those reported using the mucoadhesive 
polycarbophil formulation.26
A Phase IV , open-label, randomized, multicenter study 
designed to evaluate the pharmacokinetic properties in 
humans (Inspire Pharmaceuticals, Inc, Study 041-103) 
revealed that following single and multiple (twice daily for 
two days and once daily for the next 5 days) administration of 
azithromycin ophthalmic solution, 1%, the Cmax for aqueous 
humor was 0.053 µg/mL, but the Cmax for conjunctiva was 
over 10,000-fold higher, at 559.7 µg/g of tissue, indicating 
a substantial accumulation in conjunctiva. Total exposure to 
azithromycin, as measured by the AUC values, was also sub-
stantially greater for conjunctiva than for aqueous humor.27 
In another study performed in humans who were scheduled 
to undergo cataract surgery and received AzaSite in the 
FDA-approved dosing regimen for bacterial   conjunctivitis, 
conjunctival biopsies taken at the time of surgery were 
examined. The conjunctival concentrations of   azithromycin 
above the minimum inhibitory concentration required for 
inhibition of growth of 90% of tested bacterial isolates 
were found approximately 24 hours after the last dose. The 
concentration of azithromycin was maintained more than 
300 µg/mL after 7 days of therapy, with levels persisting Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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above 50 µg/g for 5 days after stopping the drug.28 These 
results suggested that the drug penetrates into ocular surface 
tissues in high concentrations and persists in therapeutic 
concentrations for several days after therapy is discontinued, 
unlike the fluoroquinolones that partition readily in aqueous 
solution.28 Similarly in another open-label, active-controlled 
trial in healthy adult volunteers, after a single instillation of 
AzaSite into healthy human conjunctiva, azithromycin tissue 
concentrations peaked at 30 minutes after administration and 
remained high at therapeutic concentrations at 24 hours.29 
In contrast, other studies have demonstrated that, when 
azithromycin in aqueous solution without DuraSite was 
administered topically, the concentrations of azithromycin 
in ocular surface tissues were negligible.2
Recently, the pharmacokinetics of a 2% ocular solution 
of azithromycin in DuraSite (AzaSite XtraTM) was analysed 
in forty-two male pigmented rabbits.30 Twenty-four hours 
after administration of a single drop, corneal and conjunc-
tival concentrations exceeded the minimum inhibitory 
concentration breakpoint for the most common causative 
pathogens of bacterial conjunctivitis by 3.5- and 5.8-fold, 
respectively; whereas the plasma levels were four to five 
orders of   magnitude lower than ocular tissue levels.
Safety profile and tolerability
Azithromycin ophthalmic solution has been studied at 
concentrations from 0.2% to 1% in a 14-day ocular toxicity 
study with four times daily dosing, and at 1% in two 30-day 
ocular toxicity studies with twice daily dosing in rabbits. No 
evidence of overt toxicity was observed in any study, by oph-
thalmoscopic or histopathological evaluation, as indicated by 
a lack of corneal degeneration, necrosis, inflammation, or 
edema.27 Cytoplasmic microvacuolation, most likely a mani-
festation of phospholipidosis, has been observed in corneal 
tissue sections. This was fully reversible after 60 days of 
posttreatment recovery. In rabbits treated with azithromycin 
3% formulated in DuraSite twice daily for 30 days, focal 
corneal cloudiness of minimal grade was observed which 
was slowly reversible, and was not   associated with corneal 
mineralization or other histopathological changes indicative 
of toxicity. Focal corneal cloudiness was not observed at 
concentrations of #2% in any study.
Azithromycin did not cause gene mutations in bacterial 
or mammalian cells in vitro, and did not cause chromosomal 
aberrations in human lymphocytes in vitro or mouse bone 
marrow cells in vivo.31 It has been used in adult and pediatric 
populations for over 10 years with no known association 
with carcinogenicity.27 No evidence of impaired fertility or 
teratogenicity was determined in mice or rats that received 
oral doses of #200 mg/kg/day.32
In the clinical trials, the azithromycin ophthalmic 
solution, 1% was reported to be well tolerated. The most 
  frequently reported ocular adverse reaction reported in 
  clinical trials involving subjects undergoing cataract surgery 
or subjects with blepharitis was eye irritation, which occurred 
in approximately 1%–2% of patients. Other adverse reactions 
associated with the use of AzaSite were reported in less than 
1% of patients and included: burning, stinging and irritation 
upon instillation, contact dermatitis, corneal erosion, dry 
eye, dysgeusia, nasal congestion, ocular discharge, punctate 
keratitis, and sinusitis.27 On the other hand, in a subject-
masked, randomized, active and placebo-controlled study 
that compared perceptions of subjects with normal ocular 
health for two antibiotic ophthalmic drops in contralateral 
eyes, moxifloxacin 0.5% ophthalmic solution (Vigamox®, 
Alcon Laboratories, Inc, Fort Worth, TX) was rated more 
comfortable and acceptable with less blurring than azithro-
mycin 1% in DuraSite, in both adult and pediatric popula-
tions. Ocular adverse events (redness, irritation, stinging, 
burning, dryness, itching and chemosis) were observed in 
18 (17.3%) eyes receiving azithromycin and one (1%) eye 
receiving moxifloxacin.33
The adverse effect levels for the neurological and cardio-
vascular safety studies were determined as 35,000 times and 
350 times, respectively, the maximum intended daily clinical 
dose of 1% azithromycin ophthalmic solution (0.0286 mg/kg 
for a 70 kg human).27 At the plasma concentrations found 
with the instillation of AzaSite (in the ng/mL range), no 
arrhythmogenic effects or Q-T interval prolongation were 
observed.34
For the polycarbophil polymer (DuraSite), ocular topical 
administration at 0.6% and 1.3% concentrations to albino 
rabbits three times a day for at least 52 weeks was reported to 
elicit no evidence of ocular or systemic toxicity.27   However, 
in another randomized, masked, placebo-controlled animal 
study, DuraSite medications injected into the anterior 
chamber were found to induce acute inflammatory reaction 
with direct toxic effect and acute glaucoma by trabecular 
meshwork blockage.35
Ophthalmic uses of AzaSite®
Bacterial conjunctivitis
Azithromycin 1% in DuraSite (AzaSite) is the only FDA-
approved topical formulation of azithromycin available 
and marketed in the US. Azithromycin has been shown to 
be efficacious on the most common bacterial pathogens of Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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  infective conjunctivitis (ie, Staphylococcus aureus, Haemo-
philus influenzae, Streptococcus pneumoniae) (Table 1).36 It 
is indicated for the treatment of bacterial conjunctivitis,37 with 
the recommended dosing regimen of one drop in the affected 
eye twice daily (8–12 hours apart) for the first 2 days, then one 
drop once daily for the next 5 days. Randomized controlled 
trials on AzaSite for the treatment of bacterial conjunctivitis 
are summarized in Table 2.3,15,33,38–42
In a randomized, vehicle-controlled, double-blind, 
multicenter clinical study in which patients were dosed in 
the FDA-approved dosing regimen, azithromycin ophthal-
mic solution, 1% was found to be superior to vehicle on 
days 6–7 in patients with a confirmed clinical diagnosis of 
bacterial conjunctivitis.3 Clinical resolution was achieved 
in 63.1% (82/130) of patients treated with azithromycin 
ophthalmic solution, compared to 49.7% (74/149) in patients 
that received the vehicle. The bacterial eradication rates 
were 88.5% and 66.4% in the AzaSite and vehicle groups, 
respectively. Furthermore, in a multicenter, randomised, 
investigator-masked study in adults and children with puru-
lent bacterial conjunctivitis, azithromycin 1.5% (Azyter®, 
Laboratoires Thea, Clermont-Ferrand, France) for 3 days was 
found to be noninferior to tobramycin 0.3% for 7 days, for 
clinical and bacteriological cure. Moreover, more azithromy-
cin than tobramycin patients presented an early clinical cure 
at day 3 (29.8% vs 18.6%). The safety profiles and tolerability 
of the two drugs were comparable.41
In another Phase III, parallel-group, controlled clinical 
trial that studied the efficacy of the 1% azithromycin in 
  DuraSite for the resolution of signs and symptoms in par-
ticipants with acute bacterial conjunctivitis, a regimen of 7 
drops of 1% azithromycin in DuraSite was found to be equally 
effective as 20 drops of tobramycin (65% more drops). In 
that study, AzaSite was found to eradicate pathogens that 
are resistant to azithromycin in vitro, erythromycin, and 
fluoroquinolones, which suggested that systemic breakpoints 
may not be broadly applicable to ocular surface infections.15 
A report from the active-controlled trial (clinicaltrials.gov 
NCT00105469) comparing the clinical and bacterial resolu-
tion rates in 710 patients with subjects aged 1 year or older, 
showed that the microbial eradication and clinical cure rates 
were equivalent for azithromycin 1% in DuraSite twice a day 
on days 1 and 2, followed by once daily on days 3 to 5 and 
tobramycin 0.3% four times daily for 5 days. Upon analysis of 
tolerability, azithromycin was found to be just as comfortable 
as tobramycin or vehicle.40 Similar results were also reported 
in a multicenter, randomized, investigator-masked study that 
compared six drops of azithromycin 1.5% eye drops (Azyter) 
with thirty-six drops of tobramycin 0.3% in 1043 patients 
with purulent bacterial conjunctivitis.43
A recent multicenter, randomized, investigator-masked, 
parallel-group study that included 150 children and adoles-
cents of 4–17 years old found greater bacteriologic cure with 
azithromycin 1.5% eye drops (Azyter) twice daily for 3 days, 
compared to tobramycin 0.3% every two hours for 2 days, 
then four times daily for 5 days. Clinical cure was obtained 
faster with azithromycin compared to tobramycin (48% vs 
27.3% on day 3, respectively) although similar overall cure 
rates were observed (80% vs 81.8% on day 9, respectively). 
Azithromycin treatment also eradicated bacteria that were 
defined as resistant, using classical antibiogram.42
Blepharitis and dry eye
Blepharitis is a chronic disorder producing inflammation 
of the anterior and posterior lid margin, with involvement 
of skin, mucocutaneous junction, and meibomian glands. It 
can also affect the conjunctiva, tear film, and corneal sur-
face in advanced stages and may be associated with dry eye 
disease. It has also been suggested that chronic blepharitis 
may have an inflammatory etiology,44 in addition to bacterial 
infection.45 It is the resulting inflammation of the conjunctiva 
and cornea that are believed to cause the painful symptoms 
experienced by the patient and, in severe cases, can impair 
vision.46
Given the role of bacteria as one of the possible etiological 
determinants of blepharitis,45 it is believed that azithromycin 
ophthalmic solution, 1% could provide therapeutic benefit 
for this indication. The combination of anti-inflammatory 
properties along with the high and prolonged tissue con-
centrations suggest that azithromycin ophthalmic solution, 
1% has potential to serve as a novel treatment option for 
patients experiencing signs and symptoms of blepharitis.2,47 
Additionally, the altered ordering of the meibum lipids and 
resultant alteration of phase transition temperature seen in 
meibomian gland dysfunction was shown to be restored 
toward normal after topical azithromycin treatment, as shown 
by Fourier transform infrared spectroscopy.48
In a 2-week study comparing the efficacy of topical Aza-
Site combined with warm compresses to warm compresses 
alone for the treatment of posterior blepharitis, the extent of 
lid margin redness, meibomian gland plugging, and quality 
of meibomian gland secretions improved statistically sig-
nificantly in patients in the azithromycin group but not in 
patients in the warm compress-only group.49 In a multicenter 
study that randomized patients with   moderate-to-severe 
blepharitis to warm compresses-only or warm compresses Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Table 2 Randomized controlled trials on azithromycin ophthalmic solution, for the treatment of bacterial conjunctivitis*
Author Quality Number of patients  
(age range)
Indication Dosage of  
azithromycin  
eye drop
Result
Abelson15 Clinical efficacy 159 patients received  
1% azithromycin,  
157 patients received  
0.3% tobramycin 
(1 to 83 years old)
Clinically diagnosed  
bacterial  
conjunctivitis
bid on days 1  
and 2, qd  
on days 3 to 5
Clinical resolution 79.9%  
with AzaSite®, 78.3%  
with tobramycin; bacterial  
eradication 88.1% with AzaSite®,  
94.3% with tobramycin  
at day 6 or 7
Abelson3 Clinical efficacy 130 patients received  
1% azithromycin,  
149 patients received  
vehicle
(1 to 96 years old)
Clinically diagnosed  
bacterial  
conjunctivitis
bid on days 1  
and 2, qd  
on days 3 to 5
Clinical resolution 63.1%  
with AzaSite®, 49.7%  
with vehicle; bacterial eradication  
88.5% with AzaSite®,  
66.4% with vehicle at day 6 or 7
Abelson, 
Unpublished38
Clinical efficacy 685 patients
(age not available)
Clinically diagnosed  
bacterial  
conjunctivitis
bid on days 1  
and 2, qd  
on days 3 to 5
Clinical resolution and bacterial 
eradication were significantly 
better in patients who received 1% 
azithromycin compared to patients 
who received vehicle
Heller, 
Unpublished39
Safety and  
tolerability
685 patients
(1 to 96 years old)
Clinically diagnosed  
bacterial  
conjunctivitis
bid on days 1  
and 2, qd  
on days 3 to 5
12% of patients had at least  
one adverse event in both  
groups of patients who  
received 1% azithromycin  
and who received vehicle
Protzko40 Safety and  
tolerability
343 patients received  
1% azithromycin,  
367 patients received  
0.3% tobramycin
(1 to 96 years old)
Clinically diagnosed  
bacterial  
conjunctivitis
bid on days 1  
and 2, qd  
on days 3 to 5
The most common adverse  
events were eye irritation,  
conjunctival hyperemia  
and worsening of bacterial  
conjunctivitis were observed 
in 1.1 to 1.9% of patients who  
received azithromycin and 1.1 to  
2.1% of patients who received  
tobramycin. The rates of  
microbial eradication and  
bacterial infection recurrence  
were same in both groups.
Granet33 Safety and  
tolerability
84 subjects received  
0.5% moxifloxacin and 
contralateral  
1% azithromycin,  
21 subjects received  
0.5% moxifloxacin and  
contralateral placebo,  
20 subjects received  
1% azithromycin and  
contralateral placebo
($9 years old)
Healthy subjects One drop only Moxifloxacin was rated more  
comfortable and acceptable with  
less blurring than azithromycin.  
Redness, irritation, stinging,  
burning, dryness, itching and 
chemosis were observed in 17.3%  
of eyes receiving azithromycin  
and 1% of eyes receiving 
moxifloxacin
Cochereau41 Clinical efficacy  
and safety
524 patients received 
1.5% azithromycin,  
519 patients received  
0.3% tobramycin
(4 days old to 87 years old)
Clinically diagnosed  
bacterial  
conjunctivitis
bid for 3 days Clinical resolution 87.8% with  
azithromycin, 89.4% with 
tobramycin on day 9; bacterial  
eradication 85.2% with 
azithromycin, 83.8% with  
tobramycin at day 3, and 92.8% 
vs 94.6% at day 9, respectively. 
Treatment related minor adverse 
events (ie, burning, foreign body 
sensation, discharge) were noted 
in 3 patients in azithromycin group 
and 1 patient in tobramycin group
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and topical 1% azithromycin for a 4-week course of 
treatment, the   efficacy of azithromycin was rated as excel-
lent or good in 70% of patients in the azithromycin group, 
compared with only 48% in the compress-only group at the 
end of treatment period. The improvements achieved in 
the azithromycin group persisted as long as 2 weeks after 
therapy had concluded.50 Similarly, in an open-label study of 
patients with moderate-to-severe blepharitis that evaluated 
changes in the signs and symptoms of anterior and posterior 
blepharitis after a treatment period of 4 weeks with AzaSite 
in the absence of warm compresses or eye scrubs, patient-
rated symptom scores and investigator-rated assessment of 
the clinical signs of blepharitis were significantly improved 
from baseline levels. The improvement persisted for 4 weeks 
posttreatment.51
An open-label study conducted in patients with   meibomian 
gland dysfunction also revealed that   azithromycin 1.0% 
  ophthalmic solution twice a day for 2 days, then every evening 
for a total of 30 days was effective in   achieving   significant 
improvement in the signs and   symptoms   associated with 
posterior blepharitis.52 In that study,   vision-related function, 
ocular symptoms and environmental triggers were signifi-
cantly improved after only 2 weeks of treatment, as shown 
by the reduction of the Ocular Surface Disease Index.
On  the  other  hand,  a  multicenter,  randomized, 
  investigator-masked and active-controlled study   (clinicaltrials.
gov NCT01102244) enrolled 122 adult patients with 
  moderate-to-severe blepharitis/blepharoconjunctivitis, 
  randomized to tobramycin/dexamethasone ophthalmic 
  suspension 0.3%/0.05% four times daily for 14 days or 
azithromycin ophthalmic solution 1% twice daily for 2 days 
followed by once daily for 12 days. The combination of 
tobramycin/dexamethasone provided faster   inflammation 
relief compared to azithromycin, with a statistically   significant 
lower mean total signs and symptoms score at Day 8.53
Recently, two Phase II, randomized, double-masked, 
placebo-controlled studies of different lengths (2 and 
4 weeks, respectively) have been completed (clinicaltrials.
gov NCT00894530 and NCT00892970), in which the pri-
mary outcome measure was eyelid margin erythema. Another 
study evaluated the effects of oral doxycycline100 µg twice 
daily for 2 months, oral essential fatty acids 1000 µg/day 
for 2 months, or topical AzaSite once daily for 1 month in 
expressing meibomian gland secretions before and after treat-
ment in subjects with meibomian gland dysfunction and/or 
dry eye disease (clinicaltrials.gov NCT00803452).47
Trachoma
The World Health Organization recommends the SAFE strat-
egy (ie, Surgery, Antibiotics, Facial cleanliness, Environmental 
improvement),54 with a goal of eliminating trachoma, the lead-
ing cause of infectious blindness worldwide,5,55 by year 2020. 
Azithromycin, having intracellular accumulation and long 
tissue half-life properties and high efficacy against Chlamydia 
trachomatis, represents an ideal antibiotic for this indication.
Although oral azithromycin was shown to treat trachoma 
effectively,56 an eye-drop formulation without the systemic 
side effects of oral administration would be beneficial 
in the treatment of this potentially blinding disease. In a 
randomised, controlled, double-masked, double-dummy, 
noninferiority explanatory study, azithromycin 1.5% eye 
drops (Azyter) twice daily for 2 or 3 days were noninfe-
rior to World Health Organization’s reference treatment, 
azithromycin single 20 mg/kg oral dose for the treatment of 
trachoma in children.57 Likewise, an epidemiological study 
that was carried out in the Republic of Cameroon revealed 
that after two topical mass treatments 1 year apart, which 
involved one instillation of azithromycin 1.5% in both eyes 
twice daily for 3 consecutive days, lead to reduction of active 
forms of trachoma 1 year after the second treatment, from 
Table 2 (Continued)
Author Quality Number of patients  
(age range)
Indication Dosage of  
azithromycin  
eye drop
Result
Bremond- 
Gignac42
Clinical efficacy  
and safety
73 patients received  
1% azithromycin,  
77 patients received  
0.3% tobramycin
(4 to 17 years old)
Clinically diagnosed  
bacterial  
conjunctivitis
bid for 3 days Clinical resolution 80% with  
AzaSite®, 81.8% with tobramycin  
on day 9; bacterial eradication  
94.1% with AzaSite®, 76.2%  
with tobramycin at day 3.  
itching, burning, stinging were 
noted in 1 patient in azithromycin  
group and 2 patients  
in tobramycin group.
Notes: *Table modified from McLean S, Sheikh A. Effectiveness, tolerability and safety of azithromycin 1% in DuraSite® for acute bacterial conjunctivitis. Patient Prefer 
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31.5% to 3.1% (ie, a total reduction of 90%) in a population 
of children between 1 and 10 years.58,59
Conclusion
Current literature supports the efficacy and safety of   topical 
azithromycin ophthalmic 1% solution DuraSite (AzaSite) in 
the treatment of various ocular surface disorders,   particularly 
bacterial conjunctivitis, blepharitis and dry eye. The com-
bination of anti-inflammatory properties along with high 
and prolonged tissue concentrations, particularly in the lid 
margin and ocular surface due to polycarbophil (the aque-
ous mucoadhesive polymer contained in DuraSite) suggest 
that azithromycin ophthalmic solution, 1% has potential to 
serve as a treatment option for patients experiencing a wide 
range of conditions associated with the lid margin and ocular 
surface. Treatment of trachoma with topical azithromycin 
ophthalmic 1% solution is also encouraging.
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